Thomas Mellman, MD
Psychiatry · Washington, DCNPI 1275624744
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $14,500 of the $18,900 with a category attached, or 76.7%. Eisai Inc. accounts for 99.6% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $9,978 and has fallen 99.4% since, to $60 in 2025. Among psychiatry clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 28 payments — averaging $675.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$19K
- Sanofi US Services Inc.$60
- Idorsia Pharmaceuticals US Inc$15
Across 3 payments — averaging $84,456 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$253K
What the payments were for
- Consulting fees$14,50077%
- Speaking & faculty fees$1,5008%
- Travel & lodging$2,47713%
- Food & beverage$4232%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 26 | $18,826 |
| Sanofi US Services Inc. | 1 | $60 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Dayvigo$8,848
How this compares
$18,900 in reported general payments places this provider in the 95th percentile of 226 psychiatry providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $8,687 |
| Risperidone | 13 | $266 |
| Benztropine Mesylate | 11 | $104 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Washington
- Ikechi NnawuchiWashington$624K
- James GordonWashington$20K
- Tony GoreWashington$11K
- Dwight KingWashington$10K
- Igor VolkovWashington$10K
- Joel KleinmanWashington$8K
- Vivienne GomesWashington$6K
- Irfan SaeedWashington$6K
- Arda KasaciWashington$5K
- Todd AugustusWashington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.